Indefinite Delivery Contract HHSD200201689085I

This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC as the prime contractor. The contract, valued at up to $1.25 billion, is part of the Vaccines for Children (VFC) 2015 program and provides for the delivery of various vaccines and pharmaceutical products to support federal immunization and disease prevention initiatives. Key products and services included under this multiple award IDV contract include seasonal influenza...

The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded an indefinite delivery contract to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company, to provide a range of pharmaceutical products and services under the Pandemic Influenza Preparedness and Response 2016-2021 program. The $2.11 billion multiple award contract has no set-aside designation and supports government efforts for disease prevention,...

Glaxosmithkline, LLC has been awarded a multiple-award Indefinite Delivery Contract by the Centers for Disease Control and Prevention (CDC) for the procurement of various adult vaccines under the 2024 Adult Vaccines program. The contract, valued at approximately $154.3 million with a period of performance from July 1, 2024 through June 30, 2025, encompasses the supply of twelve vaccine types including Hepatitis A, Hepatitis B, Hepatitis A&B combination, Herpes Zoster, Human Papillomavirus...

This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide adult influenza vaccines for the 2024-2025 season. The $13,916,000 multiple award IDC has a period of performance through February 28, 2025. The contract does not have any set-aside designations. Glaxosmithkline will likely provide the vaccines from its facilities in North Carolina to support the CDC's immunization programs...

Glaxosmithkline, LLC holds a multiple-award Federal Supply Schedule contract for pharmaceutical and hematology-related products under the General Services Administration Pharmaceuticals and Drugs schedule (FSS-61-IB), with a ceiling value of $3.9 billion and a period of performance extending through July 31, 2027. The primary funding agency is the Veterans Integrated Service Network 12, a civilian entity within the Department of Veterans Affairs. The contract encompasses a broad range of...

The Defense Logistics Agency Troop Support Medical awarded an indefinite delivery contract to Glaxosmithkline, LLC to supply influenza virus vaccinations. Delivery orders issued against this vehicle total over $44.5 million and require Glaxosmithkline to provide vaccines from its Research Triangle Park, North Carolina facility. Performance periods range from March 2021 to November 2021. No set-asides or subcontractors are specified. This contract aims to ensure U.S. armed forces and DLA...

The federal contract IDV award SPE2DP18D0006 is a single-award indefinite delivery contract issued by the U.S. Department of Defense (DoD) Medical Supply Chain to the pharmaceutical company Glaxosmithkline, LLC. The contract, valued at a ceiling of $27,848,725.95, enables the DoD to order influenza virus vaccines and other pharmaceutical products from Glaxosmithkline, a foreign-owned for-profit organization, over the term of the agreement. Task orders issued under the IDV provide for the firm...

This Indefinite Delivery Contract, awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh to GlaxoSmithKline, LLC, establishes a multiple-award vehicle for the procurement of adult vaccines under the VACCINES major program code. The contract was awarded on July 1, 2025, with a ceiling value of $105.3 million and an ultimate completion date of June 30, 2026. As a civilian-sector contract with no set-aside designations, this IDV leverages GlaxoSmithKline's established...

This Indefinite Delivery Contract, awarded to GlaxoSmithKline, LLC on December 31, 2024, provides the Centers for Disease Control and Prevention with adult influenza vaccines through February 28, 2026, under the 2025-6 ADULT FLU VACCINES procurement. The contract carries a ceiling value of $13.9 million and was awarded as a multiple-award indefinite delivery vehicle without set-aside designations. As the prime contractor, GlaxoSmithKline will supply flu vaccines to support the CDC's immunization...

The Defense Logistics Agency Troop Support Medical awarded an Indefinite Delivery Contract to Glaxosmithkline, LLC with a potential value of $50,705,424.00 to supply influenza virus vaccines. Under this contract, three firm fixed price delivery orders were issued for a total of $33,803,616.00 to provide vaccines from Glaxosmithkline's facility in Research Triangle Park, North Carolina. The periods of performance for the delivery orders range from August 31, 2022 through February 24, 2023. The...